Quintiles wins Resolor sales and analytics contract
Contract services major Quintiles will sell Movetis’ chronic constipation treatment Resolor (prucalopride) in Europe under a contract announced last week.
The product, which recently gained European marketing approval, will be launched in the UK and Germany in the near future with Quintiles providing sales, analytics, regulatory and pharmacovigilance services.
Chris Pepler, Quintiles’ SVP of business development and operations, said the deal shows “how leading specialty pharma companies are building partnerships that extend beyond the traditional Commercial Sales Organization (CSO) model to manage risk, increase productivity, overcome complexity and demonstrate value to stakeholders.”
Movetis CEO Dirk Reyn said: “We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company.”
